Devita, Hellman, and Rosenberg's Cancer

LWBK1006-30 LWW-Govindan-Review December 12, 2011 19:35

422 DeVita, Hellman, and Rosenberg’s CANCER: Principles and Practice of Oncology Review

Question 30.36. ALL are true of HL, EXCEPT:

A. The malignant cells known as Hodgkin cells or Reed-Sternberg (HRS)

cells represent 0.15% to 1% of the entire cell population in classic

Hodgkin’s lymphoma (cHL).

B. In lymphocyte-predominant Hodgkin’s lymphoma (LPHL), HRS cells

express B-cell antigens like CD19 and CD20.

C. In cHL, these HRS cells express the activation marker CD30, and in

many cases are CD15 positive and lack major B- and T-cell lineage

antigens.

D. HRS cells express IL-13 but lack IL-5.

Question 30.37. All of the following statements are true, EXCEPT:

A. The activator protein (AP)-1 and the nuclear factor-kappa B (NF-kB)

transcription factors are constitutively active in cHL.

B. NF-kB is the central mediator of survival and proliferation of HRS

cells in cHL.

C. Mutations of the NF-kB inhibitory gene IkBa are not important trans-

forming events in cHL in the absence of EBV or other viruses.

D. Activation of the signal transducer and activator of transcription fam-

ily (STAT3, STAT6, and STAT5a) have been found in cHL. STAT3

activation was constitutive and did not depend on IL-6, whereas

STAT6 depended on IL-13 signaling.

Question 30.38. All statements are true about the immunology of HL, EXCEPT:

A. Eosinophils stimulated by IL-5 and attracted by eotaxin inhibit the

Th2 response.

B. T cells within the HL lymphoma are CD4+, TCRab+, express the

CD38, CD69, and CD71 activation markers, but lack CD26 and the

IL-2 receptor CD25.

C. Secretion of IL-10 and TGF-b by HRS cells and the inability of

T cells to secrete IL-2 suppress an effective immune response.

D. HRS cells are not able to mount an effective immune response.

Question 30.39. NLPHL differs in several ways from the subtypes of cHL, nodular scle-

rosing, mixed cellularity, and lymphocyte depleted. All of the following

statements about NLPHL are true, EXCEPT:

A. Approximately 80% of patients with NLPHL have stage I or II disease

at the time of diagnosis.

B. In contrast with cHL, the atypical cells in NLPHL are CD45+,

express B-cell antigens (CD19, CD20, CD22, CD79a, and PAX5),

the transcription factors Oct2 and BOB.1, and the germinal center-

associated proteins Bcl6 and EMA, but lack CD15 and CD30.

C. NLPHL does not transform to DLCBL.

D. NLPHL accounts for 5% of the cases of HL. More than 90% of

patients have a clinical remission and are alive at 10 years.